The development of safe and efficient liver-specific gene delivery approaches offers new perspectives for the treatment of liver disease, in particular, liver cancer. We evaluated the therapeutic potential of hepatotropic nanoparticles for gene therapy of liver tumor. These nanoparticles do not contain a viral genome and display the hepatitis B virus L antigen, which is essential to confer hepatic specificity. It has not been shown whether a therapeutic effect could be obtained using L nanoparticles in a human liver tumor xenograft model. Rats bearing human hepatic (NuE) and non-hepatic tumors were injected with L nanoparticles containing a green fluorescent protein (GFP) expression plasmid. GFP expression was observed only in NuE-derived tumors but not in the nonhepatic tumor. The potential for treatment of liver tumors was analyzed using L nanoparticles containing the herpes simplex virus thymidine kinase gene, in conjunction with ganciclovir pro-drug administration. The growth of NuE-derived tumors in L particleinjected rats was significantly suppressed, but not of the non-hepatic tumor control. In summary, this is the first demonstration that nanoparticles could be used for delivery of therapeutic genes with anti-tumor activity into human liver tumors. This intravenous delivery system may be one of the major advantages as compared to many other viral vector systems.
Introduction
Gene therapy is recognized as one of the most promising approaches for treatment of serious diseases, including monogenic diseases, infectious diseases and cancer. 1, 2 About 60% of the clinical trial protocols for gene therapy have addressed the treatment of cancer, and a number of preclinical studies are ongoing in vitro and in vivo. Many types of therapeutic genes have been investigated, and some of them have shown anti-tumor effects. Suicide genes are one such class of therapeutic genes. 3, 4 Tumor cells expressing suicide genes become sensitive to prodrugs, and prodrug treatment can be used to kill the tumor cells specifically. Herpes simplex virus thymidine kinase (HSV-tk) gene and ganciclovir (GCV) form one of the more important suicide gene/prodrug combinations. The use of various vectors carrying HSV-tk has been reported in treatment of malignant glioma, 4, 5 head and neck cancer, 6 colorectal cancer 7 and prostate cancer. 8 Hepatocellular carcinoma (HCC) is the most common primary liver malignancy with a rising incidence worldwide. 9, 10 Unresectable HCC lack effective therapy 9, 10 and new therapeutic modalities are urgently needed. The transfer of therapeutic genes to liver tumors or to the peritumoral tissue is particularly attractive for the potential treatment of liver cancer and metastasis. 11, 12 HCC is also a target of the HSV-tk/GCV system. [13] [14] [15] [16] However, non-specific expression of suicide genes in nontarget cells may cause undesirable adverse effects, such as bone marrow suppression, 17 and for such therapeutic genes to exert their function in a target-specific manner, it is important to specifically deliver them into the target cells or tissues while obviating inadvertent gene transfer into non-target cells.
Various viral vectors, including retroviral, lentiviral, adeno-associated viral (AAV), herpes viral and adenoviral vectors are currently available for gene therapy and are being explored for (liver) cancer gene therapy in particular. [13] [14] [15] [16] These vectors do not have target selectivity which reflects the broad tropism of the viruses from which they are derived. Consequently, many vectors wind up transducing non-target cells which reduces the overall efficacy of the gene therapy approach. 18 Moreover, this lack of targeting specificity may cause unexpected adverse effects, such as bone marrow suppression, due to the inadvertent transgene expression in non-target cells. 17 Although the current vector technologies are being improved further, the development of alternative novel vector systems with improved targeting specificity, higher transduction efficiencies and improved safety is warranted.
We have recently described a novel gene delivery approach based on hepatotropic nanoparticles. 19 These nanoparticles are engineered to display the hepatitis B virus surface L antigen (HBsAg) on their surface and are devoid of viral genomes, 20 which obviates potential safety concerns related to the emergence of replication-competent viruses. These nanoparticles possess high gene transfer efficiency and show high specificity to human liver cells. 19, 21 We have succeeded in loading several different genes into the particles, and then transferring these genes into human liver cells in vitro and in vivo. In addition, L nanoparticles are easily produced by recombinant yeast cells and large-scale production of the particles has already been established, 20, 22 whereas large-scale manufacturing of clinical-grade viral vectors remains a significant obstacle that hampers its clinical implementation. 23, 24 It is not known whether nanoparticles could be used successfully for targeted delivery of therapeutic genes with anti-tumor activity into human liver tumors. As a proofof-concept and as a logical extension of our prior work, 19 we have therefore investigated the distribution of L nanoparticles in a human liver tumor xenograft rat model, using a green fluorescent protein (GFP) expression plasmid as a reporter, and analyzed their potential for treatment of liver tumors using the HSV-tk/GCV system.
Materials and methods
Purification and assays for the L protein from the yeast HBsAg L nanoparticles were prepared from the yeast cells, Saccharomyces cerevisiae AH22R À , carrying HBsAg L protein expression plasmid pGLDLIIP39-RcT. 20 The whole cell extract of the recombinant yeast was fractionated with PEG 6000, and separated twice by CsCl isopycnic ultracentrifugation and once by sucrose density gradient ultracentrifugation, as described previously. 20, 22 The level of the HBsAg L proteins in the yeast cell extracts were determined by silver-stained SDS-PAGE. The S-antigenic activity in the cell extracts was determined by the IMx system (Abbott Laboratories, Abbott Park, IL, USA) in conjunction with a microparticle enzyme immunoassay (MEIA) in accordance with the manufacturer's instructions.
Cell cultures
Two cancer cell lines were used for the in vivo studies. A spontaneously immortalized cell line derived from a fetal liver cell, NuE, 25 was kindly provided by Professor T Tadakuma (National Defense Medical College, Japan). Hepatocyte specific antigen, keratins and a-fetoprotein (AFP) were examined immunohistochemically in this cell line. Hepatocyte specific antigen and keratins were positive, but AFP was negative in NuE (data not shown). We confirmed the growth of tumor when we implanted these cells into mice or rats. We used this transformed hepatocyte cell line as a human liver tumor cell line. The human colon cancer cell line, WiDr, was obtained from American Type Culture Collection (Rockville, MD, USA). NuE cells were maintained in RPMI 1640 medium (Sigma Chemical Co., St Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; JRH Biosciences, Lenexa, KS, USA). WiDr cells were maintained in Dulbecco's modified eagle's medium (DMEM; Sigma) supplemented with 10% FBS. All cells were incubated at 371C in a humidified atmosphere of 5% CO 2 in air.
Preparation of L nanoparticles
Mammalian GFP expression plasmid (pTB701-hGFP) 26 (20 mg) under the control of the SV40 promoter or a plasmid expressing HSV-tk (pGT65-hINF-alpha) (InvivoGen, San Diego, CA, USA) (20 mg) under the control of the CMV promoter was mixed with purified L nanoparticles (100 mg of protein: 500 ml of 200 mg/ml) in phosphate-buffered saline (PBS; pH 7.2), and then packaging of these genes into the L nanoparticles was performed by electroporation (Gene Pulser II System; Bio-Rad Laboratories, Hercules, CA, USA), as described previously. 19 All experiments were carried out using these gene-containing nanoparticles.
Experimental animals
For the tumor gene therapy study using L nanoparticles, BALB/c nude mice (nu/nu, 5 weeks of age, male) and F344/N nude rats (rnu/rnu, 5 weeks of age, male) were purchased from CLEA JAPAN. All experimental procedures in this study were conducted according to the guideline of the Animal Care Committee of Keio University.
Morphological analysis
Subcutaneous tumor volume was estimated according to Carlsson's formula, 27 Hence, the largest (a) and smallest (b) superficial diameters of the tumor were measured 0, 5, 7, 9 and 12 days after transplantation of the tumors, and then the volume (V) of the tumor was calculated (V ¼ a Â b Â b/2). Statistical analysis was performed using Student's t test. All values were expressed as means7s.d.
Histological analysis
The rats that received L nanoparticles were killed 7 days after injection and tumors, brains, hearts, lungs, livers, spleens, kidneys, adrenal glands, intestines and skeletal muscles were isolated. These tissues were fixed in 4% neutralized formaldehyde, according to the method of Kamovsky, 28 and embedded using a Technovit 7100 kit (Heraeus Kulzer GmbH, Wehrheim, Germany). The blocks were sectioned at 5-mm thickness, and then GFP fluorescence in each section was observed with fluorescent microscopy (Nikon ECLIPSE E1000 with a fluorescence system) and with a laser scanning confocal microscope.
L nanoparticles transfer and prodrug treatment of rats GCV (InvivoGen, San Diego, CA, USA) as a prodrug for HSV-tk was dissolved in sterile water, according to the manufacturer's instruction. Continuous GCV administration (50 mg/kg/day) was performed using an osmotic pump (DURECT Co., Cupertino, CA, USA) on the back of the tumor-bearing rats (n ¼ 5), starting from the first day after transplantation. L nanoparticles for the expression of HSV-tk were injected on day 5 after transplantation. The effect of GCV/HSV-tk was estimated by measurement of tumor volume.
Results
Expression and characterization of L nanoparticles L nanoparticles were overexpressed in S. cerevisiae AH22R -carrying L protein expression plasmid pGLDLIIP39-RcT. 20 After fractionation of the lyses by CsCl and sucrose gradient ultracentrifugation, L nanoparticles in the various fractions were separated by SDS-PAGE which was stained with silver reagent, as described previously. 20, 22 The S-antigenic activity in the cell extracts was determined by the IMx system.
Distribution of L nanoparticles in the rat model
In pre-clinical experiments, it is important to assess the biodistribution and safety of gene transfer vectors in vivo. We adopted a xenograft rat model bearing hepatic (NuE) and non-hepatic (WiDr) cell-derived tumors. About 1 Â 10 7 tumor cells (both NuE and WiDr) were subcutaneously injected into the rear flank of the mice. To normalize the size of the tumors, tumor-bearing mice were killed, and then both NuE-and WiDr-derived tumors (5 mm in diameter) were subcutaneously transplanted into the rear flank of the same nude rat. Rats bearing large enough tumors (NuE tumor: 434.17134.8 cm 3 , WiDr tumor: 400.27146.0 cm 3 ) were injected with 100 mg (500 ml) of L nanoparticles carrying 20 mg of expression plasmids, via the tail vein (n ¼ 5). As a negative control, rats were injected with PBS. The rats were killed 7 days after L nanoparticle or PBS injection. The tumors (NuE and WiDr-derived), livers, spleens and kidneys were extracted, and the morphological differences and the weights of these tissues were compared between the L nanoparticle and PBS control groups. There were no obvious differences in growth rates or tumor sizes of the tumors of rats injected with L nanoparticles containing GFP expression plasmids versus PBS controls (Figure 1a and b, Table 1) indicating that the in vivo transfection per se does not affect tumor growth. In addition, histological examination revealed no apparent histologic abnormalities in liver, lung, brain, kidney, heart, adrenal gland, skeletal muscle, spleen and intestine of tumor-bearing rats injected with L nanoparticles versus PBS controls ( Figure 2 , Table 1 ). Moreover, intravenous delivery of L nanoparticles in the tumor-bearing animals did not significantly alter body weight or the weight of the individual organs (Table 1) , nor was there any detectable change in blood platelet count and aminotransferase level in blood as markers of hepatic acute toxicity (data not shown). Collectively, these data indicate that there was no detectable toxicity of the L nanoparticles in this rat model based on histologic and macroscopic analysis, liver transaminase levels and hematologic parameters, which further corroborates their relative safety.
GFP fluorescence was measured to investigate the distribution of L nanoparticles, after killing the rats 7 days post-injection. Following injection of the GFP nanoparticles, fluorescence was observed in the hepatic NuE-derived tumors only but not in the non-hepatic WiDr-derived tumors (Figures 3, 4a and b) . This underscores the hepatic specificity of the nanoparticles. No significant fluorescence was detectable in the NuE-or WiDr-derived tumors from rats injected with PBS control (Figure 4c and d) . Furthermore, there was no detectable fluorescence in rat liver (Figures 2 and 3) , indicating that the nanoparticles were specific for human liver tumor cells, whereas rat hepatocytes were refractory to L nanoparticle-mediated gene transfer. In addition, there was no evidence of transfection into non-hepatic tissues since only aspecific background fluorescence was Gene therapy with liver-specific nanoparticles Y Iwasaki et al apparent in brain, lung, kidney, heart, spleen, adrenal gland, intestine and skeletal muscle (Figure 2 ). This fluorescence, which could be observed through both GFP and Cy3 filters, was inherent to the examined tissue and undistinguishable from PBS controls.
Suicide gene therapy with L nanoparticles
The biodistribution studies based on GFP reporter gene expression indicate that the L nanoparticles are well suited to achieve targeted gene delivery and cell-specific expression in liver tumor. To determine whether L nanoparticles could be used for liver tumor-specific gene therapy, it was important to demonstrate that a therapeutic effect could be obtained by targeted delivery of therapeutic genes into the liver tumors. The therapeutic potential of the nanoparticles was determined by loading the particles with HSV-tk gene and by assessing the antitumor effect following GCV pro-drug administration in the rat xenograft tumor model. Continuous GCV administration (50 mg/kg/day) was performed in rats (n ¼ 5) bearing NuE hepatic tumors, starting from the first day after transplantation. L nanoparticles containing 20 mg HSV-tk expression plasmids were injected intravenously into tumor-bearing rats on day 5 after transplantation. As a control, injection of 20 mg HSV-tk plasmids alone was used. The growth of NuE-derived hepatic tumors in L nanoparticle-injected rats was significantly (Po0.05) suppressed during the course of the experiment (456.27124.5 cm 3 ), whereas NuE-derived tumor growth progressed in the control group that only received the HSV-tk genes without L nanoparticles (2120.07778.5 cm 3 ) (Figure 1c ). In contrast, there was no tumor regression following nanoparticle/HSV-tk and GCV administration in WiDr-derived non-hepatic tumor-bearing rats, compared to the WiDr tumor control group that received only HSV-tk/GCV (Figure 1d ). Moreover, there was no anti-tumor effect in the NuE and WiDr controls injected with L nanoparticles/GFP (Figure 1a and b) . There were no apparent sideeffects associated with the nanoparticle transfection, nor was there a significant difference in body or organ weight between the experimental and control groups (data not shown). Hence, these results demonstrate for the first time that L nanoparticles could be used successfully and safely for delivery of therapeutic genes with anti-tumor activity into human liver tumors with unprecedented targeting specificity, resulting in liver tumor-selective expression of the therapeutic gene.
Discussion
In the present study, we investigated the effects of L nanoparticles in vivo in a rat xenograft tumor model. The Figure 3 Fluorescence images with a laser scanning confocal microscope. 100 mg L nanoparticles containing 20 mg GFP expression plasmid were injected. Fluorescence images of NuE-derived tumors, WiDr-derived tumors, liver, lung, kidney, heart, skeletal muscle spleen on day 7 after injection. Scale bars: 500 mm. Figure 4 In vivo GFP gene delivery in the rat xenograft model. 100 mg L nanoparticles containing 20 mg GFP expression plasmid were injected in NuE-bearing rats (a) or WiDr-bearing rats (b). 500 ml PBS was injected in NuE-bearing rats (c) or WiDr-bearing rats (d). Scale bars: 20 mm. biodistribution of L nanoparticles was determined by analyzing GFP expression in hepatic and non-hepatic tumors and in various tissues. The fluorescence and histologic analysis indicate that GFP expression is restricted to and specific for the transplanted liver tumors (NuE) (Figures 2-4) , indicating that nanoparticles are well suited for targeted gene delivery and expression for human liver tumor. In the current study, a detailed histologic analysis was undertaken and the results are consistent with and extend our previous observations regarding L nanoparticle-mediated delivery of GFP or fluorescent compounds in a mouse model. 19 This tropism of the L nanoparticles for human liver tumor reflects the natural tropism of the human hepatitis B virus (HBV) which is primarily determined by the pre-S1 targeting peptide located at the N-terminal end of the L antigen. 29 The lack of GFP expression in the rat liver following L nanoparticle transfection is consistent with the resistance of rodent hepatocytes to HBV infection. 30 The hepatotropic specificity of HBV and consequently also the L nanoparticles, is determined by the interaction of the HBsAg with an elusive cellular receptor, although several candidate receptors or co-receptors have been proposed, including annexin V 31 and squamous cell carcinoma antigen-1 homolog (SCCA-1). 32 L nanoparticles are well tolerated and do not appear to induce serious adverse effects (Table 1, Figure 2) . Furthermore, L nanoparticles by themselves have no effect on tumor suppression or progression (Figure 1) .
The lack of viral genomes in the L nanoparticles obviates concerns regarding the possible generation of replication-competent viruses that may arise by homologous recombination, as in the case of early-generation adenoviral vectors and retroviral vectors. 33 Moreover, the safety profile of the L nanoparticles compares favorably compared to the safety of several viral vectors.
The immunogenicity of the L nanoparticles is controversial. The ability for repetitive administration is of paramount importance in the clinical context. Most of the world's population has antibodies against hepatitis B because of prior infection or due to immunization. Hence, the application of L particles would be limited to the patients who have no antibodies against the virus. However, HBsAg immune escape variants exist in chronic hepatitis B patients and eliminating/modifying the immunogenic epitopes from L particles could minimize these limitations.
The HSV-tk/GCV paradigm is an attractive anti-cancer gene therapy approach, because it generally provides for a potent anti-tumor response, by virtue of the bystander effect. 5, 34 However, the expression of HSV-tk in nontarget cells may result in unexpected adverse effects, because all cells transduced with HSV-tk genes become sensitive to GCV. In studies of anti-HCC therapy, an AFP promoter or enhancer has been employed to drive HSV-tk specifically into HCC cells. 35, 36 Although use of an AFP promoter or enhancer induces HCC-selective expression, the transgenes rarely work in non-or low-AFP-producing HCC cells. In this study, we attempted to express HSV-tk genes in NuE cells, which are low AFPproducing liver tumor cells. 37 L nanoparticles carrying HSV-tk genes were injected into tumor-bearing rats intravenously, and growth of NuE-derived hepatic tumors in the experimental group was suppressed in conjunction with GCV administration (Figure 1c) , whereas WiDrderived non-hepatic tumors showed progression during the course of the experiment (Figure 1d ). The suppression of tumor-growth was strictly depending on the L nanoparticles since injection of HSV-tk/GCV without nanoparticles had no effect on tumor growth (Figure 1c) . These results are consistent with the GFP biodistribution profile (Figures 2 and 3 ) and indicate that L nanoparticles can specifically deliver therapeutic transgenes into human liver cells. Nanoparticle-mediated targeted gene delivery enable liver tumor-selective expression while obviating the use of an AFP promoter or enhancer, which may not be ideally suited to target expression in HCC, especially in those cells in which AFP expression is either absent or very low. Nevertheless, it is possible that selective transgene expression in human hepatic tumor cells following nanoparticle-mediated gene transfer could be improved further when promoters are chosen that are expressed at higher levels in cancerous versus normal hepatic tissue, as identified by transcriptional profiling. 38, 39 Although it is known that the L nanoparticles also transfect normal human hepatocytes but not murine hepatocytes, 19 it has been shown that only dividing cells are susceptible to phosphorylated GCV. 40 Thus, expression of HSV-tk with L particles in quiescent normal hepatocytes followed by GCV treatment might not cause damage to normal hepatocytes but would be restricted to dividing liver tumor cells instead. This would be consistent with recent observations showing strong antitumoral efficacy in the absence of normal liver toxicity following direct intratumoral injection of a lentiviral vector containing the HSV-tk gene and GCV treatment. 16 However, this study and our current observations are in contrast with the severe liver dysfunction and mortality that arose following systemically administered hepatotropic adenoviral vectors expressing HSV-tk and GCV treatment. 41 These data further confirm that the L nanoparticles may have an improved biosafety profile compared to adenoviral vectors for hepatic gene delivery. Interestingly, intravenous injection of L nanoparticles appeared to show similar efficacy to the intratumoral injection of adenoviral vectors into large tumor nodules. 42 The current study underscores the potential of hepatotropic nanoparticles for gene therapy of liver tumor, which may pave the way towards a more efficacious and safer hepatic gene delivery approach. Future studies will require safety and efficacy analysis of the L nanoparticles in mouse models with 'humanized' liver 43 in conjunction with potent liver-tumor specific promoters to further refine the selectivity of expression.
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